ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 268

The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)

Nicola Dalbeth1, Meihana Douglas1, Kate MacKrill1, Leanne Te Karu2, Maria Kleinstäuber1 and Keith Petrie1, 1University of Auckland, Auckland, New Zealand, 2Ngā Kaitiaki o Te Puna Rongoā o Aotearoa, Taupō, New Zealand

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: gout

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Healthcare Disparities in Rheumatology Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   Recent research has suggested that renaming gout to a pathophysiological illness label (urate crystal arthritis) avoids inaccurate lay perceptions of gout and promotes more effective management strategies.  In Aotearoa/New Zealand, Māori (indigenous New Zealanders) have high prevalence of gout, with early onset and severe disease.  It is unknown how a change in illness label would impact on indigenous New Zealanders who are disproportionally affected by gout.  The aim of this study was to examine the effect of changing the illness label of gout on the perceptions of the disease and its management in Māori in Aotearoa/New Zealand.

 

Methods: Supermarket shoppers in rural and urban locations with large Māori communities were recruited into a study examining the perceptions of different types of arthritis. Participants were randomised 1:1 to complete a questionnaire examining the perception of the same disease description labelled as either ‘gout’ or ‘urate crystal arthritis’ (UCA).  Participants rated likely causal factors for the disease, illness perceptions and the usefulness of various management strategies using Likert scales. Differences between the two illness labels were tested using independent sample t-tests.

 

Results:  Completed questionnaires were available from 172 Māori participants.  The gout-labelled illness was most likely to be viewed as caused by diet (P=0.003), whereas the UCA-labelled illness was most likely to be viewed as caused by aging (P=0.001).  ‘UCA’ was seen as having a wider range of factors as responsible for the illness, with stress or worry, hereditary factors, chance and pollution more likely to be viewed as causes of ‘UCA’. ‘Gout’ was less likely to be viewed as having a chronic timeline than ‘UCA’ (mean (SD) for ‘Gout’ 6.9 (2.8) and for ‘UCA’ 7.9 (2.4), P=0.013).  ‘Gout’ was also viewed as better understood than ‘UCA’ (mean (SD) for ‘Gout’ 6.3 (3.1) and for ‘UCA’4.4 (3.3), P=0.001).  Other illness perceptions did not differ between the illness label groups. Changing to a healthier diet was perceived as more helpful for ‘Gout’ compared to ‘UCA’ (mean (SD) for ‘Gout’ 8.5 (2.3) and for ‘UCA’ 7.3 (2.7), P=0.003).  Participants also viewed stopping or restricting alcohol use as more helpful for ‘Gout’ than ‘UCA’ (mean (SD) for ‘Gout’ 8.1 (2.8) and for ‘UCA’ 7.0 (3.1), P=0.017). There were no differences between ‘Gout’ and ‘UCA’ in perceptions that adopting regular exercise, losing weight or taking long-term medications would be helpful for managing the illness (P>0.23 for all). 

 

Conclusion: In an indigenous population that is disproportionately affected by gout, causal beliefs and management strategies for a gout-labelled illness are consistent with widely-held lay beliefs that gout is a disease caused by self-inflicted dietary excess.  Renaming gout to urate crystal arthritis promotes more complex causal beliefs, a longer timeline for the disease, and is likely to avoid perceptions that dietary modification and alcohol restriction are the main strategies for effective management.

 


Disclosure: N. Dalbeth, Horizon, 5,Kowa, 5,Amgen Inc., 2,AstraZeneca/Ironwood, 2,AbbVie Inc., 8,Pfizer, Inc., 8,Janssen, 8; M. Douglas, None; K. MacKrill, None; L. Te Karu, None; M. Kleinstäuber, None; K. Petrie, None.

To cite this abstract in AMA style:

Dalbeth N, Douglas M, MacKrill K, Te Karu L, Kleinstäuber M, Petrie K. The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-effect-of-renaming-gout-to-urate-crystal-arthritis-on-illness-and-treatment-perceptions-in-maori-the-indigenous-people-of-aotearoa-new-zealand/. Accessed March 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-renaming-gout-to-urate-crystal-arthritis-on-illness-and-treatment-perceptions-in-maori-the-indigenous-people-of-aotearoa-new-zealand/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences